Research Analysts Offer Predictions for Mind Medicine (MindMed) Inc.’s FY2027 Earnings (NASDAQ:MNMD)

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Rating) – Investment analysts at HC Wainwright decreased their FY2027 earnings per share estimates for shares of Mind Medicine (MindMed) in a report released on Thursday, March 16th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of $0.14 per share for the year, down from their previous estimate of $0.18. HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.71) per share.

Several other research firms have also recently weighed in on MNMD. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $21.00 price objective on shares of Mind Medicine (MindMed) in a research report on Friday, March 10th. Canaccord Genuity Group lowered their price target on Mind Medicine (MindMed) from $22.00 to $18.00 in a research note on Monday, November 21st. UBS Group began coverage on Mind Medicine (MindMed) in a research note on Thursday, December 15th. They set a “buy” rating and a $21.00 price target on the stock. Roth Capital restated a “buy” rating and set a $25.00 price target on shares of Mind Medicine (MindMed) in a research note on Friday, December 9th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $5.00 price target on shares of Mind Medicine (MindMed) in a research note on Friday, March 10th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $30.00.

Mind Medicine (MindMed) Stock Performance

NASDAQ MNMD opened at $2.90 on Friday. Mind Medicine has a twelve month low of $2.12 and a twelve month high of $19.95. The stock has a market capitalization of $108.95 million, a PE ratio of -1.63 and a beta of 2.07. The stock has a 50-day simple moving average of $3.47 and a 200 day simple moving average of $3.84.

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Rating) last posted its quarterly earnings data on Thursday, March 9th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.22.

Insider Activity

In other news, CEO Robert Barrow sold 8,273 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $3.51, for a total value of $29,038.23. Following the sale, the chief executive officer now directly owns 238,959 shares in the company, valued at approximately $838,746.09. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 16,922 shares of company stock worth $55,237. Company insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Several large investors have recently modified their holdings of the stock. LMR Partners LLP bought a new stake in Mind Medicine (MindMed) during the 3rd quarter worth approximately $36,000. Freestone Capital Holdings LLC bought a new stake in Mind Medicine (MindMed) during the 4th quarter worth approximately $25,000. Exchange Traded Concepts LLC grew its position in Mind Medicine (MindMed) by 235.1% during the 4th quarter. Exchange Traded Concepts LLC now owns 14,955 shares of the company’s stock worth $33,000 after acquiring an additional 10,492 shares during the last quarter. Virtu Financial LLC bought a new stake in Mind Medicine (MindMed) during the 1st quarter worth approximately $29,000. Finally, Two Sigma Investments LP bought a new stake in Mind Medicine (MindMed) during the 4th quarter worth approximately $75,000. 20.44% of the stock is currently owned by institutional investors.

Mind Medicine (MindMed) Company Profile

(Get Rating)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.